| Literature DB >> 28343650 |
Elisabeth Frauger1, Liselotte Pochard2, Quentin Boucherie2, Adeline Giocanti2, Cécile Chevallier3, Amélie Daveluy4, Valérie Gibaja5, Anne-Sylvie Caous6, Céline Eiden7, Nicolas Authier8, Reynald Le Boisselier9, Marylène Guerlais10, Émilie Jouanjus11, Marion Lepelley12, Véronique Pizzoglio13, Stéphanie Pain14, Nathalie Richard15, Joëlle Micallef2.
Abstract
It is important to assess drug abuse liability in 'real life' using different surveillance systems. OPPIDUM ('Observation of illegal drugs and misuse of psychotropic medications') surveillance system anonymously collects information on drug abuse and dependence observed in patients recruited in specialized care centers dedicated to drug dependence. The aim of this article is to demonstrate the utility of OPPIDUM system using 2015 data. OPPIDUM is a cross-sectional survey repeated each year since 1995. In 2015, 5003 patients described the modality of use of 10,159 psychoactive drugs. Among them, 77% received an opiate maintenance treatment: 68% methadone (half of them consumed capsule form) and 27% buprenorphine (39% consumed generic form). Brand-name buprenorphine is more often injected than generic buprenorphine (10% vs. 2%) and among methadone consumers 7% of methadone capsule consumers have illegally obtained methadone (vs. 9% for syrup form). The proportion of medications among psychoactive drugs injected is important (42%), with morphine representing 21% of the total psychoactive drugs injected and buprenorphine, 16%. OPPIDUM highlighted emergent behaviors of abuse with some analgesic opioids (like tramadol, oxycodone or fentanyl), pregabalin, or quetiapine. OPPIDUM highlighted variations of drugs use regarding geographic approaches or by drug dependence care centers (like in harm reduction centers). OPPIDUM clearly demonstrated that collection of valid and useful data on drug abuse is possible, these data have an interest at regional, national and international levels.Entities:
Keywords: Abus de substances psychoactives; Dispositifs de surveillance et de veille sanitaire; Pharmacoepidemiology; Pharmacoépidémiologie; Postmarketing surveillance system; Prescription drug abuse; Substance-related disorders
Mesh:
Year: 2017 PMID: 28343650 DOI: 10.1016/j.therap.2017.01.010
Source DB: PubMed Journal: Therapie ISSN: 0040-5957 Impact factor: 2.070